DEVELOPMENT PROGRAMS >

DURECT is leveraging its epigenetic regulator program and proprietary drug delivery technologies to develop novel and lifesaving therapies for a wide range of diseases with few current treatment options.

DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.

INVESTOR RELATIONS >

DURECT's Investor section provides comprehensive information to existing and potential stockholders, including up-to-date stock information, financial reports, investor events and more.

PIPELINE

LEARN MORE >

INVESTORS

PIPELINE : PHASE 2

Larsucosterol (DUR-928)

The first endogenous epigenetic regulator clinically tested for the treatment of acute organ injury and chronic liver diseases.

SEE HOW IT WORKS (VIDEO)

News

Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.

November 12, 2021

DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis

November 10, 2021

DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021

November 8, 2021

VIEW ALL >